Overview
The purpose of this protocol is to generate a registry of Chinese patients with AL amyloidosis treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy.
Eligibility
Inclusion Criteria:
- 18 years and older
- newly diagnosed or refractory/relapsed AL amyloidosis
- treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy
Exclusion Criteria:
- co-diagnosis of multiple myeloma or Waldenström's macroglobulinemia


